, 2007 and Karlson et al., 2008). PTJC=Prediction of Tender Joint Count=−26.72+3.243∗[YKL-40]1/10−11.97*[EGF]1/10+15.72∗[IL-6]1/10+0.4594∗[Leptin]1/10+3.881∗[SAA]1/10+0.7388∗[TNF-RI]1/10−0.2557∗[VCAM-1]1/10+0.7003∗[VEGF-A]1/10 PSJC=Prediction of Swollen Joint Count=−26.63+3.232∗[YKL-40]1/10−11.93∗[EGF]1/10+15.67∗[IL-6]1/10+0.4578∗[Leptin]1/10+3.868∗[SAA]1/10+0.7363∗[TNF-RI]1/10−0.2548∗[VCAM-1]1/10+0.6979∗[VEGF-A]1/10

BMN 673 ic50 PPGS=Prediction of Patient Global Score=−13.489+5.474∗[IL-6]1/10+0.486∗[SAA]1/10+2.246∗[MMP-1]1/10+1.684∗[Leptin]1/10+4.14∗[TNF-RI]1/10+2.292∗[VEGF-A]1/10–1.898∗[EGF]1/10+0.028∗[MMP-3]1/10–2.892∗[VCAM-1]1/10–0.506∗[Resistin]1/10 MBDA score=round(max(min((.56∗sqrt(max(PTJC,0))+.28∗sqrt(max(PSJC,0))+.14∗PPGS+.36∗log(CRP/10^6+1))∗10.53+1,100),1))MBDA score=roundmax(min((.56∗sqrt(max(PTJC,0))+.28∗sqrt(max(PSJC,0))+.14∗PPGS+.36∗log(CRP/10^6+1))∗10.53+1,100),1)

All concentration values except that of CRP are X1/10 transformed prior to use in the algorithm. MBDA algorithm scores are integers from 1 to 100, with disease activity thresholds designed to be equivalent Everolimus order to thresholds from DAS28CRP: • MBDA algorithm scores ≤ 29 are considered low disease activity. All autoantibody assays exhibited less than 10% difference (median difference) between the two sample types (Table 3), well within the Food and Drug Administration suggested specification at ± 15% for accuracy (FDA, 2001). Phosphoprotein phosphatase All analyses for autoantibodies were calculated on raw signals in antibody biomarker measurements. An additional more stringent analysis compared the correlation coefficient and slope of linear regression. In comparison of plasma and serum matched sample sets, the correlation was 0.99 (0.98 to 1.00) with a slope of approximately

1.00, indicating little or no difference in quantitation of autoantibody signals in serum vs. plasma samples. For protein biomarkers of matched plasma and serum samples, only 67% of the biomarkers were highly correlated achieving correlation coefficients of 0.95 (range 0.33–1.00) (Table 3). The protein concentrations had a systematic shift with the slope of most markers being less than 1.00, indicating serum concentrations were measured higher for most biomarkers. The plasma EGF concentrations were not correlated with matched serum EGF concentrations (correlation coefficient of 0.33). As shown in Fig. 1A, 5 out of 12 protein biomarkers (VCAM-1, EGF, VEGF-A, MMP1 and resistin) had shifts > 15% in the median % difference in concentration across the 32 patient samples. Aside from leptin and MMP-1, median protein concentrations in plasma were lower than those in serum. While the median change for MMP-1 showed significantly greater concentrations in plasma over serum (Fig. 1A), the individual subjects in this study provided mixed results, with 12 subjects’ plasma showing lower MMP-1 concentrations and 20 subjects with greater MMP-1 concentrations.